ClinicalTrials.gg
Status unknownNCT04737967Updated Feb 4, 2021

The Potential Protective Role of Venlafaxine Versus Memantine in Paclitaxel Induced Peripheral Neuropathy

A Phase 2/3 interventional study of Venlafaxine and Memantine in Oncology Pain and Chemotherapy-induced Peripheral Neuropathy, sponsored by Mendel AI. Status unknown at 1 site in Egypt. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-02-04.

Sponsored by Mendel AI · Phase 2/3, Interventional, and Prevention

The sponsor has not verified this record recently (last verified Jan 2021), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

This is a double blinded two-arm randomized case-only interventional trial. A total of 60 patients who are to receive Paclitaxel to be included and allocated in two groups. The protocol is to be reviewed by the Research Ethics Committee of Faculty of Medicine Cairo University.

All procedure will be done in Kasr El-Einy Center of Radiation Oncology and Nuclear Medicine.

The first arm (Venlafaxine group) will receive Venlafaxine extended release (37.5 mg) tablets (Zimmerman et al., 2016).

The second arm (Memantine group) will receive memantine 10 mg once daily (Morel et al., 2016)

02

Conditions studied

  • Oncology Pain
  • Chemotherapy-induced Peripheral Neuropathy

Browse trials for

03

In context

Cancer Pain

311 studies on the registry are indexed under Cancer Pain; 74 are open to participants now.

This study's planned enrollment of 60 is close to the median of 63 across 236 interventional studies indexed under Cancer Pain.

Browse Cancer Pain studies →

Lead sponsor

This is the only study on the registry with Mendel AI as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. All patients, 18 years of age or older, with a cancer treated with Paclitaxel
  2. Patients must have a of at least 24 weeks.
  3. Patients must sign an .
  4. Patients may have a grade 0 (chemotherapy naive) or 1 neuropathy (history of prior chemotherapy) prior to entry.
  5. Patient matching high risk on the CIPN risk stratification scoring system

Exclusion criteria

Exclusion Criteria:

  1. Patients with symptomatic .
  2. Pregnant women or nursing mothers. Patients of child bearing potential must use adequate .
  3. Patients may receive no other concurrent complementary medicines during this study.
  4. Patients with neuropathy induced diabetes.
  5. Patients with severe medical problems such as uncontrolled diabetes mellitus or cardiovascular disease or active infections.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Venlafaxine Treated Arm

    Drug: Venlafaxine

  • Experimental
    Memantine Treated Arm

    Drug: Memantine

Interventions

  • Patients will receive will receive Venlafaxine extended release (37.5 mg) tablets once daily(Zimmerman et al., 2016)

  • Patients will receive memantine (10 mg) once daily (Morel et al., 2016)

06

What researchers measure

Primary outcomes

  1. Change in average daily pain intensity

    Change in average daily pain intensity as measured by the Brief Pain Inventory- Short Form (BPI-SF). Absolute change in the average daily pain intensity as measured by the Brief Pain Inventory- Short Form (BPI-SF) from baseline to the end of 6 weeks measured by item # 5 of Brief Pain Inventory Score (BPI-SF). The BPI assesses pain at its "worst," "least," "average," and "now" (current pain).

    Time frame: 6 weeks

  2. Electrophysiological studies

    nerve conduction velocity at the end of the study

    Time frame: 6 weeks

07

Study locations

1 of 1 sites recruiting
  • Faculty of Medicine Cairo University - Kasr El-Einy Center of Radiation Oncology and Nuclear Medicine
    Cairo, 11562, Egypt
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Feb 2021; primary completion for Aug 2021, 6 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 30, 2021
First posted
Feb 4, 2021
StartEst.
Feb 15, 2021
Primary completionEst.
Aug 15, 2021
CompletionEst.
Oct 1, 2021
Last update
Feb 4, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 4, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04737967
Lead sponsor
Mendel AI
Collaborators
Cairo University
Responsible party
G Fadl (Dr, Cairo University) — Principal investigator
First posted
Feb 4, 2021
Start date
Feb 15, 2021 (estimated)
Primary completion
Aug 15, 2021 (estimated)
Completion
Oct 1, 2021 (estimated)
Last update
Feb 4, 2021

Study contacts

Gehad Sayed Ahmed, MD
Contact
Gehad.S.Fadl@kasralainy.edu.eg
+201222352664

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Venlafaxine · Memantine

Start the discussion